pLIVE® In Vivo Expression and Reporter Vectors

A vector system designed to achieve long term expression in the livers of laboratory mice

• Sustained Gene Expression—Achieve long term liver gene expression in the mouse liver through 8 months post-injection.
• Versatile Platform—Available with positive control vectors expressing either lacZ or SEAP.

Maps
Click Images to Enlarge

The pLIVE Vector	The pLIVE-lacZ Vector	The pLIVE-SEAP Vector
download PDF	download PDF	download PDF

Sequences

Sequences	View/Copy
The pLIVE Vector
The pLIVE-lacZ Vector
The pLIVE-SEAP Vector

Data

Figure 1: The Promoter in the pLIVE Vector Outperforms the CMV Promoter for Long-term Liver Expression.
Figure 2: Long-term Expression of Human Placental Secreted Alkaline Phosphatase (SEAP) in Mice after Hydrodynamic Delivery of the pLIVE-SEAP Vector.
Figure 3: Strong Liver Expression of ß-galactosidase from the pLIVE-lacZ Vector after Hydrodynamic Tail Vein Injection.

Figure 1. The Promoter in the pLIVE Vector Outperforms the CMV Promoter for Long-term Liver Expression. The pLIVE-SEAP Vector (20 µg) and pCMV-SEAP (10 µg, CMV promoter-driven SEAP vector) were each delivered to four ICR mice using the hydrodynamic tail vein injection procedure and the TransIT-QR Hydrodynamic Delivery Solution (MIR 5240). At the indicated days post-injection, serum from each mouse was collected and the level of SEAP activity present was determined using the Phospha-Light™ SEAP Assay Kit (Applied Biosystems). The average SEAP activity from each group is presented.

Figure 2. Long-term Expression of Human Placental Secreted Alkaline Phosphatase (SEAP) in Mice after Hydrodynamic Delivery of the pLIVE-SEAP Vector. The pLIVE-SEAP Vector was delivered to three C57Bl/6 mice using the hydrodynamic tail vein injection procedure and the TransIT-QR Hydrodynamic Delivery Solution (MIR 5240). At the indicated times post-injection, serum from each mouse was collected and the level of SEAP activity was determined using the Phospha-Light™ SEAP Assay Kit (Applied Biosystems). Average SEAP activity at each time point is presented.

A B   Figure 3. Strong Liver Expression of ß-galactosidase from the pLIVE-lacZ Vector after Hydrodynamic Tail Vein Injection. The pLIVE-lacZ Vector (Panel A) was delivered to an ICR mouse using the hydrodynamic tail vein injection procedure and the TransIT-QR Hydrodynamic Delivery Solution (MIR 5240). At 24 hours post-injection, the liver was harvested, sectioned and stained with X-gal using the Beta-Gal Staining Kit (MIR 2600) to demonstrate ß-galactosidase activity (blue cells). The cells were then counterstained with hematoxylin and eosin Y to stain the nuclei and cytoplasms, respectively. The control mouse (lacZ negative) in Panel B was stained in parallel to Panel A and contains no detectable ß-galactosidase activity.

The pLIVE Vectors are covered by patents pending of Mirus Bio Corporation. Purchase of this product conveys a license for use of this product only for research by the purchaser in not-for-profit institutions. The purchaser may only transfer vectors modified with sequences for protein expression to researchers in not-for-profit institutions who agree to be bound by this license. This license does not include the right to perform research at or on behalf of a for-profit entity, the right to transfer unmodified vectors to others or the right to use the product for any commercial purpose (e.g. therapeutics, manufacturing, diagnostics or sale or fee-for-service use of animal models). Prospective users at for-profit institutions or those who wish to perform research on behalf of for-profit institutions or any other commercial purpose must contact Mirus Bio Corporation for a commercial license. If you require a commercial license to use this product and you decide not to take a license, please return the unopened product to Mirus Bio Corporation for a full refund.

In vivo hydrodynamic delivery of non-viral nucleic acids is covered by worldwide patents and patent applications of Mirus Bio Corporation, including U.S. Patent 6,627,616 and related filings worldwide. Purchase of these products does not provide a license to this delivery technology, which is required for all research and commercial uses by for-profit entities. To inquire about a license, please contact Mirus Bio Corporation.